Bernard-Gauthier Vadim, Collier Thomas L, Liang Steven H, Vasdev Neil
Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA.
Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA; Advion Inc., Research and Development, Ithaca, NY 14850, USA.
Drug Discov Today Technol. 2017 Nov;25:19-26. doi: 10.1016/j.ddtec.2017.09.001. Epub 2017 Oct 23.
Project-specific collaborations between academia and pharmaceutical partners are a growing phenomenon within molecular imaging and in particular in the positron emission tomography (PET) radiopharmaceutical community. This cultural shift can be attributed in part to decreased public funding in academia in conjunction with the increased reliance on outsourcing of chemistry, radiochemistry, pharmacology and molecular imaging studies by the pharmaceutical industry. This account highlights some of our personal experiences working with industrial partners to develop new PET radiochemistry methodologies for drug discovery and neuro-PET research studies. These symbiotic academic-industrial partnerships have not only led to novel radiotracers for new targets but also to the application of new carbon-11 and fluorine-18 labeling methodologies and technologies to label previously unprecedented compounds for in vivo evaluations.
学术界与制药合作伙伴之间针对具体项目的合作，在分子影像领域尤其是正电子发射断层扫描（PET）放射性药物领域日益普遍。这种文化转变部分可归因于学术界公共资金的减少，以及制药行业对化学、放射化学、药理学和分子影像研究外包的日益依赖。本文介绍了我们在与工业合作伙伴合作开发用于药物发现和神经PET研究的新PET放射化学方法方面的一些个人经历。这些学术与产业的共生合作关系不仅催生了针对新靶点的新型放射性示踪剂，还推动了新的碳-11和氟-18标记方法及技术的应用，以标记前所未有的化合物用于体内评估。
